Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medicure Inc V.MPH

Alternate Symbol(s):  MCUJF

Healthcare Biotechnology
Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company’s United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).


TSXV:MPH - Post by User

Medicure Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(23)
•••
Post by Checkouton Aug 20, 2021 4:52pm
185 Views
Post# 33741391

Over 300 million dollars yet to be announced.

Over 300 million dollars yet to be announced. PPE Is Here to Stay, and That’s Not a Bad Thing

[url=[url=https://www.supplychainbrain.com/blogs/1-think-tank/post/32667-ppe-is-here-to-stay-and-thats-not-bad]https://www.supplychainbrain.com/blogs/1-think-tank/post/32667-ppe-is-here-to-stay-and-thats-not-bad[/url]]https://www.supplychainbrain.com/blogs/1-think-tank/post/32667-ppe-is-here-to-stay-and-thats-not-bad[/url] 

MRS) is pleased to announce that, through its wholly-owned subsidiary, Unifire, Inc., the Company has been awarded a total of 7 government contracts – for personal protective equipment consisting of disposable level 2 and level 3 isolation gowns (the “Products”) – with an estimated value of $127,878,307 and a maximum value of $435,723,020 (the “C&T Contracts”) to be fulfilled over a 12-month period

https://mrscorp.com/mission-ready-awarded-new-contracts-for-an-estimated-127-million-with-a-ceiling-of-435-million/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities